ReviewHead and neck pathology2018
Update on Merkel Cell Carcinoma.
Review in Head and neck pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 42 citations in OpenAlex.
- Impact of UV Exposure and Incidence of Merkel Cell Carcinoma Between 1990 and 2018 in Austria.Cancers · 2025Article
- Common Diseases Presenting in an Uncommon Way: Metastatic Small-Cell Lung Carcinoma Mimicking Merkel Cell Carcinoma.Cureus · 2025Article
- Importance of Surgical Margins in Patients with Early-Stage Merkel Cell Carcinoma.Dermatology and therapy · 2025Article
- Rare but Still There: An Interesting Case of Cytokeratin 20-Negative Merkel Cell Carcinoma.Cureus · 2024Article
- Different expression patterns of p63 and p73 in Felis catus papillomavirus type 2-associated feline Merkel cell carcinomas and other epidermal carcinomas.The Journal of veterinary medical science · 2024Article
- Article
- Genomic Alterations and Tumor Mutation Burden in Merkel Cell Carcinoma.JAMA network open · 2023Article
- Merkel cell carcinoma presenting as a malignant pleural effusion post-COVID-19 hospitalization: A case report and literature review.Diagnostic cytopathology · 2022Article
- Merkel Cell Carcinoma of the Left Eyelid with Metastasis to the Left Submandibular Lymph Nodes: A Case Report and Brief Review.Case reports in ophthalmological medicine · 2022Article
- Merkel Cell Carcinoma of the Head and Neck: Epidemiology, Pathogenesis, Current State of Treatment and Future Directions.Cancers · 2021Review
- Long-term response to avelumab and management of oligoprogression in Merkel cell carcinoma: A case report.World journal of clinical cases · 2021Article
- An Introduction to Virus Infections and Human Cancer.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2021Article
- Avelumab as an Emerging Therapy for Eyelid and Periocular Merkel Cell Carcinoma.International ophthalmology clinics · 2020Article
- B7-H3 Expression in Merkel Cell Carcinoma-Associated Endothelial Cells Correlates with Locally Aggressive Primary Tumor Features and Increased Vascular Density.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Merkel cell carcinoma (MCC) is an aggressive cutaneous neuroendocrine carcinoma. Incidence of MCC continues to rise, and risk factors include advanced age, pale skin, chronic sun exposure, and immune suppression. Diagnosing MCC utilizes a combination of morphology and immunohistochemistry. Merkel cell polyomavirus (MCPyV) is present in approximately 70-80% of MCCs and represents a key pathogenic driver in those MCCs. In contrast, MCPyV-negative MCCs arise through progressive accumulation of ultraviolet-light induced somatic mutations. Staging of MCC proceeds according to the American Joint Commission on Cancer (AJCC) 8th Edition, which utilizes features of the primary tumor together with regional lymph node(s) (clinically and/or pathologically detected) and/or distant metastases. Many potentially useful biomarkers have been studied to refine risk stratification in MCC. In recent years, the host immune infiltrate has been leveraged as immune checkpoint blockade has emerged as an efficacious mode of treatment for patients with advanced MCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.